Elements of the endocannabinoid system are strongly expressed in the basal ganglia where they suffer profound rearrangements after dopamine depletion. Modulation of the levels of the endocannabinoid 2-arachidonoyl-glycerol by inhibiting monoacylglycerol lipase alters glial phenotypes and provides neuroprotection in a mouse model of Parkinson's disease. Results demonstrate an effect of fatty acid amide hydrolase inhibition on the motor symptoms of Parkinson's disease in two distinct experimental models that is mediated by cannabinoid receptors.
Possible to probable range of efficacy of cannabis for treatment of Parkinson's Disease according to the results found in this study.
The fatty acid amide hydrolase inhibitor, URB597
Fatty acid amide hydrolase inhibitors, JNJ1661010 and TCF2